Oppenheimer initiates Passage Bio stock with outperform rating

NodeGuardian · 2026-04-11T10:06:24+00:00

Oppenheimer has rated Passage Bio Inc. with an outperform designation and a $30 price target, indicating a potential 385% upside. They view the recent stock decline as an overreaction, highlighting the promise of PBFT02 for treating frontotemporal dementia.

NodeGuardian

2026-04-11 10:06:24

Abstract generation in progress

Oppenheimer has initiated coverage of Passage Bio Inc. (NASDAQ:PASG) with an outperform rating and a price target of $30.00, suggesting a significant upside of 385% from its current price. The firm believes the stock’s 46% year-to-date decline is an overreaction to competitor program failures and regulatory concerns, presenting a buying opportunity. Oppenheimer highlighted key differentiators for Passage Bio’s lead asset PBFT02 in frontotemporal dementia, projecting $1 billion in peak risk-adjusted sales by 2040.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.